Compare Enveric Biosciences Inc (ENVB) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Under Armour Inc Class A — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Under Armour Inc Class A trades at $7.21 (market cap $2.89B). The key difference: Under Armour Inc Class A is far larger — about 543.2× Enveric Biosciences Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | UAA | |
|---|---|---|
Market Cap | $5.32M | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $8.14 |
52-Week Low | $1.28 | $4.17 |
Enterprise Value | $408.82K | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Under Armour (UAA) trades at $7.19, up 8.77% in the last session, with a bullish technical signal from moving averages and oscillators. The stock shows mixed fundamentals, with a negative net income margin of -9.98% and ROE of -30% for 2025, but beats earnings expectations in recent quarters. Cash flow trends are volatile, with a net outflow of $361.87M in 2025, while revenue declined to $5.16B. Analyst sentiment is cautious, with a consensus price target of $5.96 below the current price, and 58.11% hold ratings.
The outlook for UAA is challenged by weak North American sales and margin pressure, offset by international growth. Investment opportunity hinges on execution of a full-price strategy and cost control, but risks include consumer resistance and macroeconomic uncertainty. With the stock trading above the consensus target, near-term upside may be limited despite technical strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
